人尿激肽原酶与脑缺血损伤研究进展  

Progress in Research on Human Urinary Kininogenase and Cerebral Ischemic Injury

作　　者：滕海娟 TENG Hai-juan(The First Affiliated Hospital of Zhejiang University,School of Medicine,Hangzhou,Zhejiang Province,310003 China)

机构地区：[1]浙江大学医学院附属第一医院,浙江杭州310003

出　　处：《中外医疗》2018年第27期196-198,共3页China & Foreign Medical Treatment

摘　　要：人尿激肽原酶(HUK)是从健康成年男性新鲜尿液中提取得到的一种丝氨酸蛋白酶,是组织型激肽原酶的一种,能将激肽原转化为激肽和血管扩张素。激肽是一种促炎多肽,组织损伤时介导多种血管、疼痛反应。激肽通过激肽受体介导,在脑组织急性缺血缺氧时发挥多重重要的神经保护作用。HUK能选择性扩张脑细小动脉,改善缺血脑组织的血供和氧供,降低脑缺血损伤后炎症级联瀑布反应,同时还能促进缺血区血管及神经再生,在临床上对急性缺血性脑血管疾病有较好的疗效,但其在脑缺血再灌注损伤过程中的具体神经保护作用机制尚不十分明确,本文综述了近年来国内外对激肽酶-激肽释放系统的组成,受体表达,生理作用以及与脑缺血再灌注损伤的相关研究进展。旨在为临床脑缺血治疗提供参考。Human urokininogenase （HUK） is a serine protease extracted from the fresh urine of healthy adult males. It is a kind of tissue-type kininogenase, which can convert kininogen into kinin and Angiotensin. Kinin is a pro-inflammatory peptide that mediates a variety of vascular and pain responses in the event of tissue damage. Kinin is mediated by kinin receptors and exerts multiple important neuroprotective effects in acute ischemia and hypoxia of brain tissue. HUK can selectively dilate cerebral small arteries, improve blood supply and oxygen supply in ischemic brain tissue, reduce inflammation cascade reaction after cerebral ischemic injury, and promote vascular and nerve regeneration in ischemic area, clinically acute Ischemic cerebrovascular disease has a good effect, but the specific neuroprotective mechanism during cerebral ischemia-reperfusion injury is not very clear. This paper reviews the kininase-kinin release system in recent years. The composition,receptor expression, physiological effects and related research progress in cerebral ischemia-reperfusion injury. It is intended to provide a reference for the treatment of clinical cerebral ischemia.

关 键 词：人尿激肽原酶 脑缺血性损伤 研究进展 

分 类 号：R74[医药卫生—神经病学与精神病学]